This paper explores excessive prices at the intersection between competition law and regulated sectors such as pharma. It was prepared as a background note for the OECD Competition Committee roundtable on “Excessive pricing in pharmaceuticals”, which took place in November 2018.

Are breast cancer survival rates higher in the United States than in the United Kingdom and France? Are a patient's chances of dying within 30 days after admission to a hospital with a heart attack lower in Canada than in Korea? Are surgeons in some countries more likely to leave “foreign...

COVID-19 is likely to leave long-lasting effects on local labour markets. It is accelerating a pre-existing trend towards automation, as firms look even more to new technologies to pandemic proof their operations. While automation offers the opportunity to boost productivity, it can also lead to...